PMID- 35435983
OWN - NLM
STAT- MEDLINE
DCOM- 20220602
LR  - 20220602
IS  - 2042-7174 (Electronic)
IS  - 0961-7671 (Linking)
VI  - 30
IP  - 2
DP  - 2022 May 26
TI  - Interventions developed to reduce secondary care utilisation in patients with 
      type 2 diabetes mellitus: a narrative review.
PG  - 116-128
LID - 10.1093/ijpp/riac009 [doi]
AB  - OBJECTIVES: To identify, describe and critically appraise the quality of studies 
      of interventions developed to reduce the rate of secondary care utilisation and 
      investigate interventions' impact on patients with type 2 diabetes mellitus 
      (T2DM). METHOD: Using a systematic approach, five databases were searched between 
      01 January 1995 and 01 February 2021 (MEDLINE, EMBASE, PsycINFO, CINAHL and 
      Cochrane database). Inclusion criteria were studies (published in English) in 
      adults with T2DM offered intervention(s) involving medicines/services/educational 
      programmes in any country or setting, with investigated outcomes including the 
      rate of hospital admission/re-admission/accident and emergency visits. Validated 
      tools were used to assess the quality and accuracy of reporting the 
      interventions. A narrative synthesis was used to frame the findings. KEY 
      FINDINGS: A total of 4670 papers were identified, which yielded a final 53 
      studies after screening against the inclusion criteria. Identified interventions 
      were complex interventions (n = 21) including at least two interventions (e.g. 
      improving medication adherence and patient education), medication management (n = 
      15), patient education programmes (n = 8), lifestyle interventions (n = 5) and 
      other interventions (n = 4; e.g. dental care). After assessing for quality and 
      effectiveness of interventions, 15 studies remained; 7 were medication management 
      interventions (e.g. use of insulin pen) and 8 were complex interventions (e.g. 
      pharmaceutical care and telehealth systems). Complex interventions showed 
      significant improvement in clinical outcomes and reduction in secondary care 
      utilisation. CONCLUSIONS: This narrative review identified potential elements of 
      an effective complex intervention to reduce healthcare utilisation in patients 
      with T2DM. These results could inform the development of interventions to be 
      tested for feasibility, before piloting to assess for outcomes that improve 
      diabetic care, reduce diabetes-related complications and minimise healthcare 
      utilisation.
CI  - (c) The Author(s) 2022. Published by Oxford University Press on behalf of the Royal 
      Pharmaceutical Society. All rights reserved. For permissions, please e-mail: 
      journals.permissions@oup.com.
FAU - Khayyat, Sarah M
AU  - Khayyat SM
AUID- ORCID: 0000-0002-0316-1825
AD  - Department of Clinical Pharmacy, Faculty of Pharmacy, Umm Al-Qura University, 
      Makkah, Saudi Arabia.
AD  - School of Pharmacy, Newcastle University, Newcastle upon Tyne, UK.
FAU - Walters, Philippa A
AU  - Walters PA
AD  - School of Pharmacy, Newcastle University, Newcastle upon Tyne, UK.
FAU - Whittlesea, Cate
AU  - Whittlesea C
AD  - UCL School of Pharmacy, University College of London, London, UK.
FAU - Nazar, Hamde
AU  - Nazar H
AUID- ORCID: 0000-0002-3168-5386
AD  - School of Pharmacy, Newcastle University, Newcastle upon Tyne, UK.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Int J Pharm Pract
JT  - The International journal of pharmacy practice
JID - 9204243
SB  - IM
MH  - Adult
MH  - *Diabetes Mellitus, Type 2/therapy
MH  - Humans
MH  - Medication Adherence
MH  - Patient Acceptance of Health Care
MH  - Secondary Care
OTO - NOTNLM
OT  - accident and emergency visit
OT  - hospital admission
OT  - hospital re-admission
OT  - secondary care utilisation
OT  - type 2 diabetes mellitus
EDAT- 2022/04/19 06:00
MHDA- 2022/06/03 06:00
CRDT- 2022/04/18 12:12
PHST- 2021/05/26 00:00 [received]
PHST- 2022/02/02 00:00 [accepted]
PHST- 2022/04/19 06:00 [pubmed]
PHST- 2022/06/03 06:00 [medline]
PHST- 2022/04/18 12:12 [entrez]
AID - 6569883 [pii]
AID - 10.1093/ijpp/riac009 [doi]
PST - ppublish
SO  - Int J Pharm Pract. 2022 May 26;30(2):116-128. doi: 10.1093/ijpp/riac009.